Eli Lilly and Company $LLY Stock Sold by Eastern Bank

Key Points

• Eastern Bank trimmed its Eli Lilly stake by 0.9%, selling 1,100 shares and retaining 115,236 shares valued at approximately $133.3 million. Lilly remains the bank’s 13th-largest holding and represents about 2% of its portfolio.
• Institutional investors and hedge funds own 82.53% of LLY, while analyst sentiment remains favorable: 25 analysts rate it a Buy, with a consensus “Moderate Buy” rating and an average price target of $1,311.96.
• Lilly reported strong quarterly results, including $8.38 in EPS and $22.97 billion in revenue, with revenue up 47.7% year over year. However, the stock’s premium valuation and reliance on continued growth in diabetes and obesity treatments leave it exposed to setbacks in those markets.

Eastern Bank reduced its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 0.9% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 115,236 shares of the company's stock after selling 1,100 shares during the quarter. Eli Lilly and Company accounts for approximately 2.0% of Eastern Bank's holdings, making the stock its 13th largest holding. Eastern Bank's holdings in Eli Lilly and Company were worth $133,337,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of LLY. Bank of America Corp DE purchased a new stake in shares of Eli Lilly and Company during the second quarter valued at approximately $13,522,666,000. Jupiter Topco LLC purchased a new position in shares of Eli Lilly and Company in the second quarter valued at $4,667,180,000. Fifth Third Bancorp increased its stake in Eli Lilly and Company by 321.3% during the 1st quarter. Fifth Third Bancorp now owns 1,963,490 shares of the company's stock worth $1,805,959,000 after buying an additional 1,497,423 shares during the period. Assenagon Asset Management S.A. increased its stake in Eli Lilly and Company by 353.7% during the 1st quarter. Assenagon Asset Management S.A. now owns 1,550,234 shares of the company's stock worth $1,425,859,000 after buying an additional 1,208,510 shares during the period. Finally, Corient Private Wealth LP acquired a new position in Eli Lilly and Company in the 2nd quarter worth $764,116,000. 82.53% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on LLY shares. Citigroup upped their price objective on shares of Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the company a "buy" rating in a research report on Wednesday, July 15th. Weiss Ratings upgraded Eli Lilly and Company from a "buy (b-)" rating to a "buy (b)" rating in a research note on Wednesday, August 26th. Guggenheim increased their price target on Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the company a "buy" rating in a report on Friday, September 18th. Wall Street Zen downgraded Eli Lilly and Company from a "strong-buy" rating to a "buy" rating in a report on Sunday, August 23rd. Finally, Wells Fargo & Company upped their target price on Eli Lilly and Company from $1,280.00 to $1,330.00 and gave the company an "overweight" rating in a research report on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, twenty-five have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Eli Lilly and Company has an average rating of "Moderate Buy" and an average target price of $1,311.96.

Insider Buying and Selling

In other Eli Lilly and Company news, EVP Patrik Jonsson sold 6,500 shares of the business's stock in a transaction on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the completion of the sale, the executive vice president owned 54,147 shares in the company, valued at $63,628,139.70. The trade was a 10.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald A. Zakrowski sold 2,000 shares of the stock in a transaction on Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the sale, the chief accounting officer directly owned 1,526 shares in the company, valued at $1,808,325.26. This trade represents a 56.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 13,500 shares of company stock worth $15,958,170 over the last ninety days. 0.14% of the stock is owned by insiders.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: The FDA expanded Jaypirca (pirtobrutinib) approval to first-line treatment of adults with chronic lymphocytic leukemia or small lymphocytic lymphoma without a 17p deletion. The decision, supported by Phase 3 BRUIN CLL-313 results, broadens Lilly’s commercial opportunity in blood cancer and strengthens its oncology portfolio. FDA Expands Eli Lilly's Blood Cancer Drug Label in First-Line Setting
• Positive Sentiment: Lilly continues to show momentum in obesity care. Reports highlight strong patient growth and market-share gains against Novo Nordisk, while early data for next-generation treatments targeting the amylin pathway suggest potential for future combination therapies beyond Zepbound. Eli Lilly Targets Amylin Pathway to Unlock Next Generation Obesity Drug Combinations
• Positive Sentiment: The company expanded its multi-year collaboration with Gate Bioscience to discover small-molecule medicines for difficult-to-drug proteins, adding longer-term pipeline potential. Lilly will also present 21 dermatology studies, including encouraging durability data for Ebglyss and research involving Taltz and Zepbound. Gate Bioscience Expands Collaboration and License Agreement with Lilly
• Neutral Sentiment: Analysts and financial coverage continue to emphasize Lilly’s strong competitive position in diabetes and obesity treatments, supported by manufacturing capacity, patents and a broad pipeline. The shares’ elevated valuation means substantial future growth may already be reflected in expectations. Eli Lilly’s Valuation Has Changed
• Negative Sentiment: Several obesity-drug developments are based on early or exploratory data, so future efficacy, safety, regulatory and commercial outcomes remain uncertain. Any setbacks could weigh more heavily on LLY because its premium valuation depends on sustained growth from this market.

Eli Lilly and Company Stock Up 1.0%

NYSE LLY traded up $11.42 on Monday, hitting $1,154.27. 808,786 shares of the stock traded hands, compared to its average volume of 2,975,996. The company has a current ratio of 1.35, a quick ratio of 1.00 and a debt-to-equity ratio of 1.41. The stock has a 50-day moving average of $1,176.33 and a 200 day moving average of $1,089.48. Eli Lilly and Company has a twelve month low of $783.85 and a twelve month high of $1,292.65. The company has a market capitalization of $1.09 trillion, a P/E ratio of 38.74, a price-to-earnings-growth ratio of 1.40 and a beta of 0.46.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, topping the consensus estimate of $6.40 by $1.98. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.The company had revenue of $22.97 billion during the quarter, compared to analyst estimates of $20.82 billion. During the same quarter last year, the firm earned $6.31 EPS. The business's revenue was up 47.7% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, analysts expect that Eli Lilly and Company will post 36.66 earnings per share for the current fiscal year.

Eli Lilly and Company Company Profile

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer's disease.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.